Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

Here, we describe a genome-editing tool based on the temporal and conditional stabilization of clustered regularly interspaced short palindromic repeat- (CRISPR-) associated protein 9 (Cas9) under the small molecule, Shield-1. The method can be used for cultured cells and animal models.

Abstract

The clustered regularly interspaced short palindromic repeat- (CRISPR-) associated protein 9 (CRISPR/Cas9) technology has become a prevalent laboratory tool to introduce accurate and targeted modifications in the genome. Its enormous popularity and rapid spread are attributed to its easy use and accuracy compared to its predecessors. Yet, the constitutive activation of the system has limited applications. In this paper, we describe a new method that allows temporal control of CRISPR/Cas9 activity based on conditional stabilization of the Cas9 protein. Fusing an engineered mutant of the rapamycin-binding protein FKBP12 to Cas9 (DD-Cas9) enables the rapid degradation of Cas9 that in turn can be stabilized by the presence of an FKBP12 synthetic ligand (Shield-1). Unlike other inducible methods, this system can be adapted easily to generate bi-cistronic systems to co-express DD-Cas9 with another gene of interest, without conditional regulation of the second gene. This method enables the generation of traceable systems as well as the parallel, independent manipulation of alleles targeted by Cas9 nuclease. The platform of this method can be used for the systematic identification and characterization of essential genes and the interrogation of the functional interactions of genes in in vitro and in vivo settings.

Introduction

CRISPR-Cas9 which stands for "clustered regularly interspaced short palindromic repeats-associated protein 9" was first discovered as part of studies on bacterial adaptive immunity1,2. Today, CRISPR/Cas9 has become the most recognized tool for programmable gene editing and different iterations of the system have been developed to allow transcriptional and epigenetic modulations3. This technology enables the highly precise genetic manipulation of almost any sequence of DNA4.

The essential components of any CRISPR gene e....

Protocol

1.The DD-Cas9 vector

  1. Obtain DD-Cas9 vector from Addgene (DD-Cas9 with filler sequence and Venus (EDCPV), Plasmid 90085).
    ​NOTE: This is a lentiviral DD-Cas9 plasmid with a U6 promoter that drives the single guide RNA (sgRNA) transcription while the EFS promoter drives the DD-Cas9 transcription. The DYKDDDDK sequence (flag-tag) is present at the C-terminal of Cas9 followed by 2A self-cleaving peptide (P2A) that separates DD-Cas9 and modified fluorescent protein Venus (mVenus).

Representative Results

To enable the conditional expression of Cas9, we developed a dual lentiviral vector construct consisting of a U6-driven promoter to constitutively express sgRNA, and an EF-1α core promoter to drive the expression of the DD-Cas9 fusion protein (Figure 1A)19. As a paradigm to illustrate the robustness and efficiency of the system, we transduced the lung carcinomatous A549 cell line with the lentiviral construct. The levels of Cas9 i.......

Discussion

The CRISPR/Cas9 technology has revolutionized the capability of functionally interrogate genomes2. However, the inactivation of genes often results in cell lethality, functional deficits, and developmental defects, limiting the utility of such approaches for studying gene functions7. Additionally, constitutive expression of Cas9 may result in toxicity and the generation of off-target effects6. Different approaches have been developed to temporally co.......

Acknowledgements

We thank previous members of our laboratory and scientist Serif Senturk for previous work. We thank Danilo Segovia for critically reading this manuscript. This study was possible and supported by Swim Across America and the National Cancer Institute Cancer Target Discovery and Development Center program.

....

Materials

NameCompanyCatalog NumberComments
100mM DTTThermosfisher
10X FastDigest bufferThermosfisherB64
10X T4 Ligation BufferNEBM0202S
colorimetric BCA kitPierce23225
DMEM, high glucose, glutaMaxThermo Fisher10566024
FastAPThermosfisherEF0654
FastDigest BsmBIThermosfisherFD0454
Flag [M2] mouse mAbSigmaF1804-50UG
Genomic DNA extraction kitMacherey Nagel740952.1
lipofectamine 2000Invitrogen11668019
Phusion High-Fidelity DNA PolymeraseNEBM0530S
oligonucleotidesSigma Aldrich
pMD2.GAddgene12259
polybreneSigma AldrichTR-1003-G
psPAX2Addgene12260
QIAquick PCR & Gel Cleanup KitQiagen28506
secondary antibodiesLICOR
Shield-1Cheminpharma
Stbl3 competent bacterial cellsThermofisherC737303
SURVEYOR Mutation Detection KitTransgenomic/IDT
T4 PNKNEBM0201S
Taq DNA PolymeraseNEBM0273S
α-tubulin [DM1A] mouse mAbMilliporeCP06-100UG

References

  1. Jinek, M., et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 337, 816-821 (2012).
  2. Al-Attar, S., Westra, E. R., van der Oost, J., Brouns, S. J.

Explore More Articles

CRISPR Cas9Gene EditingConditional Cas9 StabilizationShield 1Essential GenesTumor Survival GenesDD Cas9In VivoIn VitroBlood brain BarrierHEK293T CellsTransfectionVirus SupernatantVirus Titer

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved